Updated: Apr 8, 2022
The Fat-loss Peptide
12.5-fold more effective than HGH for fat-burning
Does not cause changes in glucose levels & tolerance, insulin sensitivity, or IGF-1 levels
Increased energy levels
Stimulates lipolysis and inhibits lipogenesis
More suitable for fat-burning than HGH
Higher secretion of IGF-1 may have anti-aging effects
A dose of 300- 600 mcg is administered daily. Most commonly 300mcg is administered twice daily for 3-6 months.
Buy Research Quality HGH Frag 176-191 from USA here
Buy Research Quality HGH Frag 176-191 from Canada here
HGH Frag 176-191 is an artificially created modified form of amino acids 171-191 at the C terminal region of the human growth hormone. It stimulates lipolysis, breakdown of fats and other liquids by hydrolysis, as well as enhances the synthesis of fatty acids and triglycerides from glucose.
Mechanism of Action
HGH Fragment 176-191 is a modified form of amino acids 176-191 of the human growth hormone. It imitates the method by which naturally HGH regulates fat metabolism but without antagonistic effects on insulin sensitivity or cell proliferation.
Lypolysis and Fat Reduction
Fragment 176-191 has earned the nickname of “lipolytic fragment” because testing in mice has revealed the peptide to have substantial fat burning and weight loss properties. It is thought that this action is mediated through an increase in production of beta-3 adrenergic receptors (β3-AR or ADRB3). Agonist action at ADRB3 is known to directly increase fat burning in adipose tissue and is also responsible thermogenesis in skeletal muscle. Mice that have been genetically modified to produce no ADRB3 do not respond to the lipolytic effects of hGH or fragment 176-191.
Studies show that the increased fat burning associated with fragment 176-191 directly correlates with energy expenditure and thus weight reduction, leading to a nearly 50% reduction in weight gain in obese animals over a three-week course. Interestingly, the weight loss effects were seen only in obese mice, with lean mice maintaining normal body weight, on average, even when exposed to fragment 176-191. These findings indicate that there are secondary regulatory pathways for lipolysis that override ADRB3 function when body weight is at or near ideal, opening up areas for additional research into energy homeostatsis.
1. Fragment 176-191 and Blood Sugar
Research in animals has revealed that the c-terminal end of hGH is primarily responsible for the protein’s hypoglycemic (lowering blood sugar) effects. Testing of at least six different fragments derived from this section of hGH has shown that fragment 176-191 is the most effective synthetic derivative of hGH for lowering blood sugar levels. This effect is secondary to a sustained increase in plasma insulin levels. There is some interest in using fragment 176-191 as a treatment for both prediabetes and type 2 diabetes.
3. Fragment 176-191 and Cartilage Regeneration
Though fragment 176-191 is primarily of interest for its lipolytic properties, the peptide is under investigation for other possible benefits. Of note, a 2015 article out of Korea revealed that fragment 176-191 may be able to potentiate the effects of hyaluronic acid injections in promoting cartilage regeneration. Studies in rabbits indicated that weekly injections of fragment 176-191 increase laboratory measures of cartilage growth and that co-administration of the peptide with hyaluronic acid (HA) produces even more substantial effects. Similarly, the study found that fragment 176-191, both alone and in combination with HA, reduces disability associated with osteoarthritis. There is hope that this may lead to advanced therapies for osteoarthritis and may even eliminate the need for surgery in certain settings.
A study conducted by Natera & Jiang, 1994, examined the potential of hGH Fragment 177-191 as a treatment for obesity and meat quality in farm animals. Using a mouse model they determined that treatment with hGH 177-191 promoted an overall reduced cumulative body weight gain and a decrease in the adipose tissue mass. This suggests that hGH Fragment 177-191 has potential to be a potent anti-obesity treatment.
Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochemistry and Molecular Biology International. 1994 Aug;33(5):1011-1021. PMID: 7987248.
All information found on vantanexcorp.com, and its associated blog is intended for informational and entertainment use only. Vantanex Corp does not provide medical advice. Vantanex Corp tries to provide the most recent and up-to-date research however can make no guarantees this is the case. Vantanex Corp does not condone the use of illegal drugs or the use of drugs for unintended purposes. Before taking any medication, over-the-counter drugs or medication, seek medical advice from a medical professional. No liability will be assumed for the use of these articles, the contained information is not medical advice.
To learn more about Vantanex Corp' Terms and Conditions of Buying, click here.